We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
2.00 | 2.40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
- |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
- | O | 0 | 2.20 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
22/1/2024 | 07:00 | RNSNON | Cambridge Nutritional Sciences PLC Scientific Educational Webinar and.. |
18/12/2023 | 15:51 | UKREG | Cambridge Nutritional Sciences PLC Holding(s) in Company |
04/12/2023 | 07:00 | RNSNON | Cambridge Nutritional Sciences PLC Scientific Educational Programme.. |
28/11/2023 | 15:56 | UKREG | Cambridge Nutritional Sciences PLC Holding(s) in Company |
23/11/2023 | 07:00 | UKREG | Cambridge Nutritional Sciences PLC Half-year Report |
22/11/2023 | 10:59 | UKREG | Cambridge Nutritional Sciences PLC Holding(s) in Company |
20/11/2023 | 11:09 | UKREG | Cambridge Nutritional Sciences PLC Holding(s) in Company |
17/11/2023 | 12:55 | UKREG | Cambridge Nutritional Sciences PLC Holding(s) in Company |
10/11/2023 | 07:00 | UKREG | Cambridge Nutritional Sciences PLC Warrant Expiry and Block Admission.. |
06/11/2023 | 07:00 | UKREG | Cambridge Nutritional Sciences PLC Notice of Results and Investor.. |
Omega Diagnostics (ODX) Share Charts1 Year Omega Diagnostics Chart |
|
1 Month Omega Diagnostics Chart |
Intraday Omega Diagnostics Chart |
Date | Time | Title | Posts |
---|---|---|---|
31/12/2023 | 20:43 | Omega Diagnostics | 11,924 |
23/11/2023 | 07:08 | short of money | 169 |
10/10/2023 | 19:59 | Omega Diagnostics - nicely poised for significant growth | 16,443 |
06/9/2023 | 07:47 | Omega Diagnostics Group Plc | 866 |
11/6/2023 | 21:50 | Bullshit Free Zone | 634 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|
Top Posts |
---|
Posted at 31/8/2023 12:53 by twatcher I bet the "safe haven for all reasonable ODX shareholders.", is really loving this, those reasonable ODX shareholders wouldn't possibly be critical...would they ? |
Posted at 31/8/2023 07:39 by terminator101 No company that has ever done a share consolidation has done well for existing investors. "Provides more options for the company in the future" tells you everything you need to know ;-) |
Posted at 14/8/2023 09:16 by terminator101 Finally they post their results. No wonder they wanted to try and stall. Revenue down. Losses up. But nice that Jay more than doubled his salary to £351,000 So don't worry as no director has suffered any hardship as a result of the "transformation" of the share price. |
Posted at 25/7/2023 11:24 by hooded claw Oh dear, GDR rise was due to a field ODX have nothing to do with |
Posted at 21/3/2023 07:01 by xtrmntr The cash flow statement is the first thing I go to when looking at the financial statements.We're going to do a walkthrough on a company that was popular last year called Omega Diagnostics (ODX).What went wrong?This is a company that got caught up in the testing hype, then failed to deliver on its revenues.Some blame the government. Some blame the board.But regardless of who is to blame, the warning signs were clear in the cash flow statement.Cash flow statements show how cash moves through the business and can tell us if a company:may need to raise moneyconverts its profits into cashis spending hefty amounts on capexBy the end of this email, you'll know how to work your way around the three parts of the cash flow statement.Let's get started on the first part: the cash flow statement of operations. Operating cash flow statement (OCF)The operating cash flow statement shows if a business is self-sustaining in its ordinary course of business.It starts with the company's bottom line (net income/loss) and then works its way back to cash generated/used from operations by the company.To do this, the company adjusts items on its P&L.Let's look at ODX's cash flow statement.Source: SharePad (risk-free trial and free month worth £74 here)This company made a £2.7m loss in its half-year report.But it doesn't mean that it used £2.7m from its cash reserves.This is where the OCF comes in handy.For example, we can see straight away that the company adjusts for depreciation.Depreci |
Posted at 29/1/2023 13:41 by thirty fifty twenty hi misterxyes i agree completely. in particular i have researched the CFO's patterns and involvement with the other PLC's he has been involved with in the past and then too (twice) he has bought at prices before then selling the business to an outsider at much higher prices (12-18mths later). also they are both heavily incentivised with share options etc... so why spend real money when one is going to be rewarded anyway, unless it seems like an excellent risk/reward. the only negative scenario i could contemplate is that they are trying to inflate the price ... now they dont need to do that to raise funds (since they have c.5m net CASH in the bank) but it was for acquisitions? so i see that as a possibility (albeit outside) but one which i would be happy with as any acquisitions increase the size of the MV which brings in more investors which typically gives the overall company a higher rating. so, for me, all the scenerios seem positive. though the biggest sign overall is the fantastic chart which has obviously shaken the crash from the covid mania peaks and is now forming a very strong recovery pattern. All IMHO, DYOR + BoL ODX is in my top5 holdings |
Posted at 25/11/2022 15:16 by smithie6 Masuremguysorry, but I am right. if you disagree then please give me the name of just 1 other listed company that has made this same stupid mistake ? I don't think you can because ODX is the only co. to have made this stupid mistake. It is false reporting. ----- either ODX needs to correct its stated owners of >3% or all the other listed companies need to correct their accounts & website to copy the ODX mistake. That would be X hundred/thousand companies. !! |
Posted at 25/11/2022 13:38 by smithie6 btwI think there is 1 mistake in your write up it mentions cash raise at 5p, whereas I think you meant "at 4p" ---- "On 6 May 2022, Omega announced its intention to raise gross proceeds of up to £4.1 million by way of a Placing, Subscription and Open Offer (together the "Fundraising"), all at an issue price of 4 pence per New Ordinary Share." ---- I think it would be useful, if you could consider to update your write up to make it clear what is the situation of the building that ODX plans to move to. For example - is it being built for ODX (I think yes, either built or modified) - does ODX have any TNAV in it or is it all going to be a leased building ? - ODX now don't plan to move until 2025 I think. Does ODX have to pay any rental/lease costs in '23 or '24 if the building is ready but ODX leaves it empty ?? I don't know. I think various ppl would like to know. |
Posted at 31/3/2022 15:58 by hedgehog 100 What is a fair EV (enterprise value) valuation for ODX, before and after a bid.Well, IDH (Immunodiagnostic Systems Holdings) was taken over last May for c. £110M., an enterprise value of c. £88M. IDH's full year sales to 31.3.21 were £32.7M., and the H1 loss was about £3M. = An EV sales multiple of c. 2.7. Assuming full year ODX sales of say c. £12M., and applying a sales multiple of say c. 1.35, gives a value of c. £16M., or about 9p/share. I.e. well over double the current share price. And a bid could see that multiple moving much higher. That looks like a pretty good margin of safety to me, at the current share price of 3.85p. 17/05/2021 07:00 UK Regulatory (RNS & others) PerkinElmer Inc Offer for Immunodiagnostic Systems Holdings Plc LSE:IDH Immunodiagnostic Systems Holdings Plc " ...The boards of PerkinElmer, Inc. ("PerkinElmer") and Immunodiagnostic Systems Holdings PLC ("IDS") are pleased to announce that they have reached agreement on the terms of a recommended all cash offer whereby the entire issued and to be issued ordinary share capital of IDS will be acquired by PerkinElmer (UK) Holdings Limited ("PerkinElmer UK") (the "Acquisition"). -- Under the terms of the Acquisition, each IDS Shareholder will be entitled to receive: 382 pence in cash per IDS Share -- The Acquisition values the entire issued and to be issued ordinary share capital of IDS at approximately GBP110 million ($155 million), on the basis of a fully diluted share capital of 28,865,469 IDS Shares. This implies an enterprise value of IDS of approximately GBP88 million ($124 million). -- The price of 382 pence in cash per IDS Share represents a premium of approximately: -- 49.8 per cent. to the Closing Price of 255 pence per IDS Share on the Last Practicable Date; -- 58.1 per cent. to the Volume Weighted Average Price per IDS Share during the one month period ended on the Last Practicable Date; -- 68.2 per cent. to the Volume Weighted Average Price per IDS Share during the three month period ended on the Last Practicable Date; and -- 72.5 per cent. to the Volume Weighted Average Price per IDS Share during the five year period ended on the Last Practicable Date. ..." |
Posted at 18/3/2022 15:51 by sanks SpecialGypo.. My nob is next to the Christmas tree..feel free to stroke it on the way out..thank you...or you might want to consider ODX as the skirt is lifted towards £1.10 and above.. Just look at GDR today!!!..ODX share price was hand in hand with GDR recently..so this is an easy £1.10 target!! 30.00 GBX +13.75 (84.62%)today 18 Mar, 16:06 GMT |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions